• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    5/9/24 4:31:07 PM ET
    $ADMA
    $AIH
    $CDNA
    $CLSD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities
    Health Care
    Get the next $ADMA alert in real time by email

    Gainers

    • Sensus Healthcare (NASDAQ:SRTS) shares increased by 33.3% to $5.08 during Thursday's after-market session. The market value of their outstanding shares is at $83.2 million. As per the news, the Q1 earnings report came out today.
    • TELA Bio (NASDAQ:TELA) shares moved upwards by 13.36% to $5.6. The company's market cap stands at $138.0 million. As per the press release, Q1 earnings came out today.
    • CareDx (NASDAQ:CDNA) stock increased by 13.01% to $12.5. The company's market cap stands at $650.1 million. The company's, Q1 earnings came out today.
    • Natera (NASDAQ:NTRA) stock moved upwards by 12.42% to $107.5. The market value of their outstanding shares is at $13.1 billion. As per the press release, Q1 earnings came out today.
    • Sharecare (NASDAQ:SHCR) shares moved upwards by 9.59% to $0.75. The market value of their outstanding shares is at $271.2 million. As per the press release, Q1 earnings came out today.
    • ADMA Biologics (NASDAQ:ADMA) shares moved upwards by 9.23% to $7.57. The market value of their outstanding shares is at $1.7 billion. As per the news, the Q1 earnings report came out today.

    Losers

    • Macrogenics (NASDAQ:MGNX) stock fell 55.6% to $6.51 during Thursday's after-market session. The market value of their outstanding shares is at $407.2 million. As per the press release, Q1 earnings came out today.
    • Progyny (NASDAQ:PGNY) stock decreased by 20.0% to $26.0. The company's market cap stands at $2.4 billion. As per the news, the Q1 earnings report came out today.
    • Aesthetic Medical Intl (NASDAQ:AIH) shares fell 13.8% to $0.44. The company's market cap stands at $21.0 million.
    • Clearside Biomedical (NASDAQ:CLSD) shares declined by 8.15% to $1.24. The market value of their outstanding shares is at $92.6 million. The company's, Q1 earnings came out today.
    • eFFECTOR Therapeutics (NASDAQ:EFTR) stock decreased by 6.98% to $2.0. The company's market cap stands at $9.4 million.
    • Monopar Therapeutics (NASDAQ:MNPR) shares declined by 6.82% to $0.67. The company's market cap stands at $11.7 million. The company's, Q1 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADMA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADMA
    $AIH
    $CDNA
    $CLSD

    CompanyDatePrice TargetRatingAnalyst
    ADMA Biologics Inc
    $ADMA
    3/26/2026Overweight → Neutral
    Cantor Fitzgerald
    Sensus Healthcare Inc.
    $SRTS
    3/6/2026$7.50Buy
    Alliance Global Partners
    Progyny Inc.
    $PGNY
    1/20/2026$30.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Monopar Therapeutics Inc.
    $MNPR
    1/9/2026$115.00Overweight
    Morgan Stanley
    Progyny Inc.
    $PGNY
    1/8/2026$34.00Hold → Buy
    Truist
    Natera Inc.
    $NTRA
    1/7/2026$300.00Buy
    Citigroup
    CareDx Inc.
    $CDNA
    1/6/2026$26.00Buy → Hold
    Craig Hallum
    Progyny Inc.
    $PGNY
    12/9/2025$29.00Overweight
    Barclays
    More analyst ratings

    $ADMA
    $AIH
    $CDNA
    $CLSD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ADMA Biologics downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded ADMA Biologics from Overweight to Neutral

    3/26/26 8:39:56 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Alliance Global Partners initiated coverage on Sensus Healthcare with a new price target

    Alliance Global Partners initiated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $7.50

    3/6/26 8:35:41 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Progyny upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Progyny from Mkt Perform to Mkt Outperform and set a new price target of $30.00

    1/20/26 8:45:21 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $ADMA
    $AIH
    $CDNA
    $CLSD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

    WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar," the "Company," "we") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the fourth quarter and full-year 2025 financial results and provided a summary of recent developments. "2025 was a productive year for Monopar, marked by multiple ALXN1840 data presentations, an important publication, a strengthened balance sheet and continued progress toward a planned New Drug Application submission for ALXN1840 in Wilson disease," said Chandler Robinson, MD, Chief Executive Officer of Monopar. "We also recently strengt

    3/27/26 1:00:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sensus Healthcare Files Lawsuit Against SkinCure Oncology for Breach of Contract

    Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the filing of a lawsuit in the Circuit Court for the Fifteenth Judicial Circuit in and for Palm Beach County, Florida, against SkinCure Oncology, LLC (SkinCure) alleging breach of contract related to unpaid amounts owed for Sensus products that have been delivered, accepted and deployed into clinical use. The complaint alleges that SkinCure has failed to remit millions of dollars for medical equipment that SkinCure has used since August 2025, but now refuses to p

    3/27/26 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research

    Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and Therefore, May Not Respond to Vaccines Highlights that Demand for – and Utilization of – ASCENIV Has Grown Steadily Over Past Two Years and is at Record High Details that Stocking Levels Maintained by ADMA's Distributors Align with Industry Standards and Reflect the Long Production Cycle for ASCENIV RAMSEY, N.J. and BOCA RATON, Fla., March 27, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company ded

    3/27/26 7:00:00 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    $AIH
    $CDNA
    $CLSD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Elms Steve bought $217,420 worth of shares (14,000 units at $15.53) (SEC Form 4)

    4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

    3/9/26 9:14:42 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sachetta Eric bought $7,620 worth of shares (2,000 units at $3.81), increasing direct ownership by 1% to 142,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    2/26/26 9:25:34 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Vu Quan Anh bought $104,925 worth of shares (1,500 units at $69.95) (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    12/29/25 12:15:31 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMA
    $AIH
    $CDNA
    $CLSD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for MARGENZA issued to MACROGENICS INC

    Submission status for MACROGENICS INC's drug MARGENZA (SUPPL-5) with active ingredient MARGETUXIMAB-CMKB has changed to 'Approval' on 05/25/2023. Application Category: BLA, Application Number: 761150, Application Classification:

    5/29/23 4:45:45 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for XIPERE issued to CLEARSIDE BIOMEDICAL, INC

    Submission status for CLEARSIDE BIOMEDICAL, INC's drug XIPERE (ORIG-1) with active ingredient TRIAMCINOLONE ACETONIDE has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form

    10/25/21 2:22:37 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SUSVIMO issued to CLEARSIDE BIOMEDICAL, INC

    Submission status for CLEARSIDE BIOMEDICAL, INC's drug SUSVIMO (ORIG-1) with active ingredient RANIBIZUMAB has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form

    10/25/21 2:07:19 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMA
    $AIH
    $CDNA
    $CLSD
    SEC Filings

    View All

    Monopar Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Monopar Therapeutics (0001645469) (Filer)

    3/27/26 1:27:25 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Monopar Therapeutics Inc.

    10-K - Monopar Therapeutics (0001645469) (Filer)

    3/27/26 1:00:33 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Progyny Inc.

    SCHEDULE 13G/A - Progyny, Inc. (0001551306) (Subject)

    3/27/26 11:19:23 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $ADMA
    $AIH
    $CDNA
    $CLSD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sheena Jonathan

    4 - Natera, Inc. (0001604821) (Issuer)

    3/20/26 9:05:06 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form 4 filed by Clapp Geoffrey

    4 - Progyny, Inc. (0001551306) (Issuer)

    3/19/26 5:12:56 PM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    Director Chapman Rowan E sold $23,348 worth of shares (122 units at $191.38), decreasing direct ownership by 2% to 5,752 units (SEC Form 4)

    4 - Natera, Inc. (0001604821) (Issuer)

    3/17/26 9:05:05 PM ET
    $NTRA
    Medical Specialities
    Health Care

    $ADMA
    $AIH
    $CDNA
    $CLSD
    Leadership Updates

    Live Leadership Updates

    View All

    Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

    WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar" or the "Company"), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created executive role, Ms. Rodriguez will lead the Company's commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson d

    3/2/26 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income(1) of $161 Million, Representing 35% Year-Over-Year Growth FY 2025 Adjusted EBITDA(2) of $231 Million, Representing 40% Year-Over-Year Growth Incoming CFO Appointment Expected to Further Enhance Financial Strategy, Working Capital Execution and Capital Allocation Discipline Advancing SG-001 Pipeline Program with Anticipated FDA Pre-IND Meeting in 2026; Potential Accelerated Path to Registrational Trial Ongoing Share Repurchases and Capital Structure to Increase Stockholder Value Reiterating Previo

    2/25/26 4:05:00 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer

    Kennedy brings seven years of public company CFO experience CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that Keith Kennedy, the Company's Chief Operating Officer (COO), will also assume the responsibilities of Chief Financial Officer (CFO) and oversee the Company's finance organization effective February 26, 2026. Kennedy brings to CareDx over 20 years of experience and executive leadership in healthcare including global diagnostics, biopharma services, and contrac

    2/24/26 5:15:00 PM ET
    $CDNA
    Medical Specialities
    Health Care

    $ADMA
    $AIH
    $CDNA
    $CLSD
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

    Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan

    6/22/24 8:00:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMA
    $AIH
    $CDNA
    $CLSD
    Financials

    Live finance-specific insights

    View All

    TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results

    MALVERN, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Delivered revenue of $20.9 million in the fourth quarter and $80.3 million for the full year 2025, an 18% and 16% increase, respectively, from the corresponding periods of 2024;Expanded the sales force to 88 quota-carrying representatives as of today under the leadership of commercial management added at midyear;Announcing promotion of Howard Langstein, MD, FACS to Chief Medical Officer

    3/24/26 4:05:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    TELA Bio to Announce Fourth Quarter and Full Year 2025 Financial Results

    MALVERN, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report fourth quarter and full year 2025 financial results on Tuesday, March 24, 2026. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Fourth Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15

    3/10/26 4:05:00 PM ET
    $TELA
    Medical/Dental Instruments
    Health Care

    Natera Reports Fourth Quarter and Full Year 2025 Financial Results

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the fourth quarter and full year ended December 31, 2025. Recent Financial Highlights Generated total revenues of $665.5 million in the fourth quarter of 2025, compared to $476.1 million in the fourth quarter of 2024, an increase of 39.8%. Product revenues grew 39.8% over the same period. Generated a gross margin1 of 66.9% in the fourth quarter of 2025, compared to a gross margin1 of 62.9% in the fourth quarter of 2024. Generated total revenues of $2,306.1 million in the full year 2025, compared to $1,696.9 million in the full year 2024, an increase of 35.9%.

    2/26/26 4:05:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    $ADMA
    $AIH
    $CDNA
    $CLSD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Monopar Therapeutics Inc.

    SC 13D/A - Monopar Therapeutics (0001645469) (Subject)

    12/17/24 5:01:42 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Progyny Inc.

    SC 13G/A - Progyny, Inc. (0001551306) (Subject)

    12/6/24 10:11:35 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by MacroGenics Inc.

    SC 13G - MACROGENICS INC (0001125345) (Subject)

    11/20/24 10:44:27 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care